For example, high PUS7 expression levels are associated with poor survival in patients with glioblastoma (21); Ψ in difficult-to-treat subsets of MDS is characterized by high risk of progression to acute myeloid leukaemia (22); miR-10b modulates U6 N-6-adenosine Ψ promoting glioblastoma tumorigenesis (23); loss of NOP10 and subsequent reduction in H/ACA box snoRNAs and rRNA Ψ inhibited lung cancer tumorigenesis (24); lacking SNORA24-guided Ψ is associated with liver cancer tumorigenesis (25). Here, PUS7 is linked to myelodysplastic syndrome.